Endo Int'l (ENDP): Path To 50% Upside - Guggenheim

October 14, 2016 6:38 AM EDT
Get Alerts ENDP Hot Sheet
Price: $20.81 +1.36%

Rating Summary:
    17 Buy, 20 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 14 | Down: 11 | New: 8
Trade ENDP Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Guggenheim analyst, Louise Chen, reiterated her Buy rating on shares of Endo International plc (NASDAQ: ENDP) noting that shares have given back the gains that the stock made when it announced on 9/23/2016 that Paul Campanelli will replace Rajiv De Silva as CEO (now down 20% vs. -1.5% for the S&P 500), trading back to levels where it was before the announcement.

ENDP has been quiet on any transformative changes, one outcome that the analyst believes could drive shares 50% higher or more is for ENDP to sell the brand business and non-core international assets, pay down debt, and focus on generics. After this, ENDP may do better as a private company given the Street's focus on drug pricing and lack of visibility into Par's generic pipeline in '18+. Interestingly, ENDP said it is focusing on a portfolio review, and therefore will not attend healthcare conferences in 4Q16.

No change to the price target of $35.

For an analyst ratings summary and ratings history on Endo International plc click here. For more ratings news on Endo International plc click here.

Shares of Endo International plc closed at $19.81 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities

Standard & Poor's, Louise Chen, Guggenheim

Add Your Comment